We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
- Authors
Simonitsch-Klupp, I.; Hauser, I.; Ott, G.; Drach, J.; Ackermann, J.; Kaufmann, J.; Weltermann, A.; Greinix, H.T.; Skrabs, C.; Dittrich, C.; Lutz, D.; Pötter, R.; Mannhalter, C.; Lechner, K.; Chott, A.; Jaeger, U.
- Abstract
To define reproducible criteria for subgroups of diffuse large B-cell lymphomas (DLBCL), including lymphomas with plasmablastic/plasmacytoid features (PB/PC-Fs), we investigated 66 DLBCL; the samples were categorized as either centroblastic (CB), immunoblastic (IB) or PB/PC-F applying standardized morphologic criteria. Blinded specimens were reviewed by three independent pathologists. The final consensus classification included 44 CB (67%), seven IB (10%) and 15 PB/PC-F (23%). The interobserver agreement between two centers (Vienna, Würzburg) was 93.5%. Most PB/PC-F were CD20+, cIgM+, MUM-1+, CD138±, bcl-6-, corresponding to an activated B-cell phenotype. Immunoglobulin-VH gene mutation analysis was consistent with a germinal or postgerminal center-cell origin. By fluorescence in situ hybridization analysis, 11/13 (85%) PB/PC-F had a monoallelic TP53 deletion. The pretreatment characteristics of patients with PB/PC-F included a tendency for more B symptoms, extranodal disease and a higher IPI. Importantly, PB/PC-F were resistant to standard chemotherapy (complete remission rate 47%, relapse rate 71%) and even autologous stem-cell transplantation. The median overall survival (OS) (14 months, P<0.002) and disease-free survival (6 months, P=0.02) were significantly shorter compared to patients with CB and IB. The OS difference was pronounced within the low and low-intermediate IPI risk group (P<0.001). Our data indicate a strong association of plasmablastic/plasmacytoid morphology with TP53 deletions, poor response to chemotherapy and short survival.Leukemia (2004) 18, 146-155. doi:10.1038/sj.leu.2403206 Published online 6 November 2003
- Subjects
B cell lymphoma; P53 protein; LEUKEMIA; SPONTANEOUS cancer regression; BIOLOGICAL variation; TUMORS
- Publication
Leukemia (08876924), 2004, Vol 18, Issue 1, p146
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/sj.leu.2403206